NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against James Hardie Industries plc ("James Hardie" or the "Company") (NYSE:JHX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by […]
NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ModivCare, Inc. ("ModivCare" or "the Company") (NASDAQ:MODV). Investors who purchased ModivCare securities prior to November 3, 2022, and continue to hold to the present, are encouraged to obtain additional
NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lamb Weston Holdings, Inc. ("Lamb Weston" or "the Company") (NYSE:LW). Investors who purchased Lamb Weston securities prior to July 25, 2023, and continue to hold to the present, are
NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. ("PACS Group" or "the Company") (NYSE:PACS). Investors who purchased PACS Group securities prior to April 11, 2024, and continue to hold to the present, are encouraged
Firm Wins “Best Law Firm,” “Best Personal Injury Lawyer,” “Best Accident Lawyer,” “Best Law Customer Service,” and celebrates 34 Years of Serving the Las Vegas Community Adam S. Kutner, Injury Attorneys, the leading personal injury law firm in Las Vegas and proud official partner of the Vegas Golden Knights, is celebrating a landmark achievement with
NEW YORK, NY / ACCESS Newswire / December 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities prior to March 7, 2024, and continue to hold to the present, are encouraged to obtain additional information
(NASDAQ:DYN), WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET GlobeNewswire December 07, 2025 WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage
https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased Marex securitiesduring the Class Period you
New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you